Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Acq. announced
Quarterly results
Appointed director
CC transcript
PLUS THERAPEUTICS, INC. (CYTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/16/2019 GN Cytori Will Become Plus Therapeutics, Inc.
07/11/2019 GN Cytori to Present Corporate Update & New Strategic Direction
07/01/2019 GN Cytori Reports Summary of FDA Feedback Regarding its ATI-1123 Product
06/27/2019 GN Cytori Announces New Annual Stockholders Meeting Date for July 11
06/19/2019 GN Cytori Announces New Annual Stockholders Meeting Date for June 27
06/13/2019 GN Cytori to Present New Strategic Direction
05/14/2019 GN Cytori Reports Q1 2019 Business and Financial Results
04/23/2019 GN Japan Cell Therapy Transaction Yields $3MM
04/01/2019 GN Cytori Reports Fourth Quarter and Full Year 2018 Business and Financial Results
03/07/2019 GN Cytori Files Pre-submission Request for New Drug Application
12/03/2018 GN Cytori Announces Japan Class III Medical Device Approval for Cell Therapy Product
10/30/2018 GN Cytori Therapeutics Announces Receipt of Puregraft® Royalty Milestone
09/17/2018 GN Phase 2 Ready Oncology Drug Receives FDA Orphan Drug Designation
08/31/2018 GN Cytori Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
08/14/2018 GN Cytori Reports Q2 2018 Business and Financial Results
08/09/2018 GN Cytori Reports Publication of Interim Pilot Data for Cell Therapy in Vocal Fold Scarring
07/24/2018 GN Cytori Announces $6.7 Million in Expected Gross Proceeds from Recently Expired Rights Offering
07/16/2018 GN Cytori Reminds Stockholders That Rights Offering Expires on Friday, July 20
07/08/2018 GN Cytori Reports Sustained Benefit of Cell Therapy in Erectile Dysfunction Trial
06/28/2018 GN Cytori Reports Improved Skin Healing in Pivotal Burn Preclinical Study
06/22/2018 GN Cytori Therapeutics Reminds Investors of Today??s Deadline to be a Shareholder of Record
06/12/2018 GN Cytori Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
05/23/2018 GN Cytori Therapeutic's common stock to begin trading on adjusted basis on May 24, following one-for-ten reverse split
05/10/2018 GN Cytori Reports Q1 2018 Business and Financial Results
05/07/2018 GN Cytori to Webcast First Quarter Financial Results on May 10
03/28/2018 GN Enrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy™ for Stress Urinary Incontinence
03/08/2018 GN Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results
02/22/2018 GN Cytori to Webcast Fourth Quarter Financial Results on March 8th
02/15/2018 GN Cytori Scleroderma Trial Data Presented at Systemic Sclerosis World Congress
02/09/2018 GN Cytori Therapeutics Announces Inducement Grants for New Employees
01/22/2018 GN Enrollment Completed in Randomized Clinical Trial of Habeo™ Cell Therapy for Scleroderma and Impaired Hand Function
11/28/2017 GN Cytori Closes Rights Offering for Gross Proceeds of $10 Million
11/24/2017 GN Cytori Announces Expiration of Oversubscribed Rights Offering
11/20/2017 GN Cytori Reports Reduction in Fibrosis Parameters in Scar Study
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy